PathoVax, LLC is a private biotechnology startup co-founded by PhD graduates from the Johns Hopkins University (JHU) located in Baltimore Maryland, USA. PathoVax’s pilot product offering is RGVax, a bi-valent prophylactic Human Papillomavirus (HPV) vaccine that protects against all clinically relevant HPVs in a rapidly growing US$2 billion vaccine market. Proof of concept studies of the mono-valent RGVax prototype were published in two peer reviewed journals showing protection against 27 HPV types in vivo. This 27 HPVs include all 15 cancer causing HPVs and 12 clinically relevant skin HPV types which are non-sexually transmitted. This is a significant improvement over current HPV vaccines that protect against a maximum of 9 types. PathoVax is now working on a finalized formulation which aims to extend protection to ALL CLINICALLY RELEVANT HPV types. By creating a protection profile that nears universal coverage against all HPVs, RGVax is an attractive platform for pharmaceutical firm...
PathoVax, LLC is a private biotechnology startup co-founded by PhD graduates from the Johns Hopkins University (JHU) located in Baltimore Maryland, USA. PathoVax’s pilot product offering is RGVax, a bi-valent prophylactic Human Papillomavirus (HPV) vaccine that protects against all clinically relevant HPVs in a rapidly growing US$2 billion vaccine market. Proof of concept studies of the mono-valent RGVax prototype were published in two peer reviewed journals showing protection against 27 HPV types in vivo. This 27 HPVs include all 15 cancer causing HPVs and 12 clinically relevant skin HPV types which are non-sexually transmitted. This is a significant improvement over current HPV vaccines that protect against a maximum of 9 types. PathoVax is now working on a finalized formulation which aims to extend protection to ALL CLINICALLY RELEVANT HPV types. By creating a protection profile that nears universal coverage against all HPVs, RGVax is an attractive platform for pharmaceutical firms looking to conquer this ‘winner-takes-all’ market.

Unlike other vaccine or biologic start-ups that require immediate, capital intensive investments to perform costly preclinical work such as clinical grade manufacturing and human clinical trials, PathoVax is in a unique position whereby its initial start-up investment to acquire and develop RGVax up to Phase I clinical trials is significantly discounted due to non-dilutive funding awarded by the US National Institutes of Health estimated at US$5 million. Specifically, this support was awarded to the Dr. Reinhard Kirnbauer (an inventor of the original HPV vaccines) and Dr. Richard Roden (HPV vaccine research expert), who are co-inventors of RGVax technology. These funds will support the clinical grade manufacturing scale-up, toxicology and clinical trial administrative guidance (investigational new drug application application). The significantly lower investment capital required and the NIH validation bolsters greater attractiveness to RGVax for sustained follow-on investment which ensures PathoVax’s success in this time-intensive, risky market with an extremely promising return on investment
More information

Advisors

Recommendations

Phillip Phan Advisor at PathoVax

Josh, with his team, is getting ready to change the world. Defying the odds of getting a vaccine launched, Josh has fired the imagination of venture capitalists, public health advocates, doctors, and patients to see an end to a global scourge on human health. The technology being commercialized represents a new development platform for the next generation multi-valent vaccines to combat communicable human disease. Josh is not only a solid scientist, he is a pragmatic businessperson and a compassionate leader.